Literature DB >> 30561027

Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease.

Monica A Konerman1, Patrick Walden2, Megan Joseph2, Elizabeth A Jackson2, Anna S Lok1, Melvyn Rubenfire2.   

Abstract

BACKGROUND: Lifestyle interventions are first-line therapy for non-alcoholic fatty liver disease (NAFLD). AIMS: To examine the prevalence of NAFLD among participants of the University of Michigan Metabolic Fitness (MetFit) Programme and to assess the impact of this programme on weight, metabolic and liver-related parameters among patients with and without NAFLD.
METHODS: Adults who completed the programme between 2008 and 2016 were included. Clinical and laboratory data were collected at enrolment, and at 12 and 24 weeks. NAFLD was defined based on liver biopsy, imaging or clinical diagnosis.
RESULTS: The cohort (N = 403; 253 12-week, 150 24-week) consisted primarily of middle-aged (median 54 years) white (88%) men (63%) with severe obesity (median BMI 37.4). 47.6% met criteria for NAFLD. At baseline, NAFLD patients were younger (52 vs 55 years), had higher weights and more metabolic derangements (higher fasting insulin and triglyceride, lower high-density lipoprotein-cholesterol). At programme completion, 30% achieved weight reduction ≥5%, 62% resolution of hypertriglyceridaemia, 33% resolution of low HDL, 27% resolution of impaired fasting glucose and 43% normalisation of alanine aminotransferase. Endpoints were unaffected by NAFLD. Longer programme duration (OR 6.7, 95% CI 3.6-12.3) and white race (OR 3.83, 95% CI 1.04-1.76) were independent predictors of ≥5% weight loss.
CONCLUSIONS: Nearly half of the patients referred to a structured lifestyle programme for metabolic syndrome had NAFLD. Although baseline metabolic derangements were more pronounced among NAFLD patients, the programme was equally efficacious in achieving weight loss and resolving metabolic syndrome components. Programme duration was the most important predictor of response.
© 2018 John Wiley & Sons Ltd.

Entities:  

Year:  2018        PMID: 30561027     DOI: 10.1111/apt.15063

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

Review 1.  Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jay H Shubrook; Leon A Adams; Kim Pfotenhauer; Vincent Wai-Sun Wong; Eugene Wright; Manal F Abdelmalek; Stephen A Harrison; Rohit Loomba; Christos S Mantzoros; Elisabetta Bugianesi; Robert H Eckel; Lee M Kaplan; Hashem B El-Serag; Kenneth Cusi
Journal:  Gastroenterology       Date:  2021-09-20       Impact factor: 33.883

2.  Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction.

Authors:  Alexandria Miller; Jennifer McNamara; Scott L Hummel; Matthew C Konerman; Monica A Tincopa
Journal:  Sci Rep       Date:  2020-07-24       Impact factor: 4.379

3.  Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study.

Authors:  Junzhao Ye; Xuan Hu; Tingfeng Wu; Yanqin Wu; Congxiang Shao; Fuxi Li; Yansong Lin; Shiting Feng; Wei Wang; Bihui Zhong
Journal:  Diabetol Metab Syndr       Date:  2019-06-15       Impact factor: 3.320

4.  Impact of a Pilot Structured Mobile Technology Based Lifestyle Intervention for Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Monica A Tincopa; Angela Lyden; Jane Wong; Elizabeth A Jackson; Caroline Richardson; Anna S Lok
Journal:  Dig Dis Sci       Date:  2021-05-03       Impact factor: 3.487

5.  Association between Non-Alcoholic Fatty Liver Disease and Mediterranean Lifestyle: A Systematic Review.

Authors:  Catalina M Mascaró; Cristina Bouzas; Josep A Tur
Journal:  Nutrients       Date:  2021-12-23       Impact factor: 5.717

6.  Association between Physical Activity and Non-Alcoholic Fatty Liver Disease in Adults with Metabolic Syndrome: The FLIPAN Study.

Authors:  Catalina M Mascaró; Cristina Bouzas; Sofia Montemayor; Miguel Casares; Cristina Gómez; Lucía Ugarriza; Pere-Antoni Borràs; José Alfredo Martínez; Josep A Tur
Journal:  Nutrients       Date:  2022-03-03       Impact factor: 5.717

7.  The Additive Values of the Classification of Higher Serum Uric Acid Levels as a Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease.

Authors:  Jie He; Junzhao Ye; Yanhong Sun; Shiting Feng; Youpeng Chen; Bihui Zhong
Journal:  Nutrients       Date:  2022-08-31       Impact factor: 6.706

8.  Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review.

Authors:  Siôn A Parry; Leanne Hodson
Journal:  Adv Ther       Date:  2020-03-07       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.